1. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. (1st January 2018) Authors: Tang, Xiaolong; Chen, Longzhou; Li, Amin; Cai, Shiyu; Zhang, Yinci; Liu, Xueke; Jiang, Zhenyou; Liu, Xinkuang; Liang, Yong; Ma, Dong Journal: Drug delivery Issue: Volume 25:Number 1(2018) Page Start: 1484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗